{
  "docId": "019de071-b74f-770c-80cd-22f6f746fca1",
  "docSlug": "da6e8db4dad70fc7ff4e589a15b2ab41",
  "documentTitle": "BioNTech | Results Presentation Deck | 40 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 40,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes immunobridging data and efficacy summary across age groups.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b74f-770c-80cd-22f6f746fca1/13",
  "deckHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1",
  "deckJsonHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1.json",
  "deckAnchorHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.52,
        "y": 0.24
      },
      "kind": "callout",
      "text": "BNT162B2 efficacy across age groups",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f37f2f1-3e56-4c9f-a635-f01662d2d30c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "chart",
      "text": "50% serum neutralizing titer bar chart comparing before vaccination and 1 month after dose 2 across four cohorts.",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c06d6c1-65f6-43ca-97d3-02a9120d8166",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.04,
        "y": 0.7
      },
      "kind": "list",
      "text": "Two doses of 10µg administered 21 days apart; Well tolerated with mainly transient mild-to-moderate side effects; Robust neutralizing antibody responses similar (GMT of 1,197.6) compared to control group 16 to 25 years old (GMT of 1,146.5)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "534ea506-7c76-437f-b864-b8b90f6948d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.52,
        "y": 0.75
      },
      "kind": "list",
      "text": "Further pediatric expansion: Pediatric cohorts: 2-5 years and 6 months to 2 years of age; Data expected in late Q4 2021 or early Q1 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ed408e3-a01b-4806-8fab-8e1814ff926e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.07,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "These data are currently under review by the regulatory authorities and have been submitted for publication. The vaccine has received U.S. EUA for 5 to <12 year olds. A decision has not yet been issued in the E.U.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1dad725-2994-4475-9822-82bd8a886af0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.04,
        "y": 0.1
      },
      "kind": "title",
      "text": "Clinical Data Support Label Extension of BNT162b2 to Children 5 to 11 Years of Age",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a19fd933-5158-43d7-a5d9-d1e2b5f10983",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "3ef0a596-8c25-4f98-9ce3-ac572ab324b0",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The presentation provides key messages and takeaways on COVID-19 vaccine reach and therapeutic modalities",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 6,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "e3928016-4f85-43ef-b051-6dae022547eb",
      "evidence": "The presentation provides a clear logic chain of performance and pipeline growth",
      "position": 0,
      "objective": "To demonstrate BioNTech's strong performance and pipeline expansion",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}